Search bioRxiv⌕ Search

bioRxiv · 10.64898/2026.11.12.760042

De novo design of antiviral monobody binders

Abstract

Monobodies (Mobs) are a class of immunoglobulin (Ig)-like proteins that have emerged as promising therapeutic scaffolds for applications ranging from antiviral therapy to cancer treatment. Unlike conventional monoclonal antibodies (mAbs), Mobs can be readily expressed in Escherichia coli at high yields, offering important advantages in overall developability. However, discovering antigen-specific Mobs with high binding affinity traditionally requires screening large, randomized in vitro libraries. To optimize Mob discovery, we developed MobGen, a computational pipeline for de novo design of Mob binders against viral antigens. As a proof of concept, we generated Mobs that bind the SARS-CoV-2 Spike glycoprotein Receptor Binding Domain (RBD). Subsequent in silico optimization improved production yield, thermal and conformational stability, binding affinity, and antiviral activity, demonstrating a promising approach for rapidly developing antibody-like molecules that target viral entry. These findings highlight MobGen's potential for de novo design of Mobs against emerging viruses with pandemic potential.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Moreira, P., Xiao, S., Conceicao, C. J. F., Alenquer, M., Silva, D. H., Parada, M., Marques, M. C., Schimdt, J., Buga, C. C., Cruz-Oliveira, C., Rodrigues, J., Miranda, M. P. d., Vieira-da-Silva, B., Wei, Y., Collado, J., Rodriguez-Espinosa, M. J., Arranz, R., Georgeon, S., Santiago, C., Valpuesta, J. M., Veiga, A. S., Castanho, M. A. R. B., Abreu, I. A., Amorim, M. J., Vicente, J. B., Correia, B. E., Soares, C. M., Lousa, D.. 2026-11-16. De novo design of antiviral monobody binders. https://doi.org/10.64898/2026.11.12.760042

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Structural basis of SBDS dysfunction in Shwachman-Diamond Syndrome

Surveillance of functional centers in the mature 60S ribosomal subunit by SBDS licenses its translational debut. Timely release of eIF6 from 60S by SBDS is essential to permit 40S joining. Biallelic mutations in SBDS associated with Shwachman-Diamond syndrome (SDS), an inherited ribosomopathy, impair dissociation of eIF6 from 60S. How SBDS variants that bind to 60S structurally perturb the maturation and surveillance of 60S is yet to be deciphered. Here, we report high-resolution cryogenic electron microscopy (cryo-EM) structures of human SBDS and pathogenic variants in complex with human 60S. The structures reveal that disease mutations disrupt key interactions of SBDS with the functional centers of the 60S subunit destabilizing critical bases and protein interactions across the P-site, peptidyl transferase center, polypeptide exit tunnel and GTPase-associated center. These mutations remodel the N-terminal contacts with 60S, altering critical interactions with uL16 (RPL10) distant from the mutation site. Mutations in domains II and III trigger conformational changes that propagate across the entirety of SBDS and remodel distant ribosomal regions, revealing an elegant mechanism of pathogenic allostery. The profound effects of SBDS mutations on both the surveillance and mature conformation of the 60S subunit provide a structural framework for understanding the molecular pathology of SDS.

biochemistry↗

Deep sequence-function mapping reveals computationally unpredictable epistatic trajectories that drive laboratory evolution

The black-box nature of directed evolution has been constraining advances in enzyme engineering and the wider application of engineered biocatalysts. While conventional deep sequence-function mapping has delivered insights into sequence space architecture, it lacks the ability to analyse adaptive landscapes and fully grasp the long-term impact of epistasis on the accessibility of evolutionary trajectories. Here, we introduce Deep Evolutionary Trajectory Mapping (dETM) which tracks the winners of a multi-round evolutionary campaign to map catalytic rates across the adaptive landscape of an imine reductase. We identified founder variants as stepping stones towards fitness peaks and recognise positive epistasis as their competitive advantage over alternative lineages. State-of-the-art machine learning models could not predict the resulting winning trajectories, which highlights the importance of decoding design principles for successful evolution experimentally. Permissive selection and ultrahigh-throughput screening emerge as foundations of derisking landscape traversal by keeping multiple paths accessible and avoiding diminishing returns.

biochemistry↗

Discovery of cell-permeable inhibitors for human succinyl-CoA:glutarate-CoA transferase

Glutaric Aciduria Type I (GA-1) is a recessive, serious neurometabolic disorder characterized by a build-up of toxic metabolites in the lysine metabolic pathway with no current pharmacological treatment. Previous mouse studies have shown that a deficiency in SUGCT attenuates the accumulation of some of these metabolites in vivo. These results highlight the potential for SUGCT as a therapeutic target in treating GA-1. We had previously identified biochemical inhibitors for SUGCT and had solved the crystal structure of the protein, both apo and bound to an inhibitor. However, we were unable to demonstrate cellular activity for these compounds. In this study, we report findings from additional in vitro high-throughput screening and address these challenges by developing an improved cell-based assay to detect SUGCT inhibition. We show that by improving the permeability of valsartan using its ethyl ester prodrug, SUGCT is effectively inhibited in GA-1 cells. We also identify meclofenamic acid as a new SUGCT inhibitor with cellular activity, providing additional validation and highlighting this enzyme target potential for GA-1.

biochemistry↗